A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Sponsor
Pfizer (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04607421
Collaborator
Ono Pharmaceutical Co. Ltd (Industry), Merck KGaA, Darmstadt, Germany (Industry)
765
396
5
70.8
1.9
0

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that:

  • has spread to other parts of the body (metastatic);

  • has a certain type of abnormal gene called "BRAF"; and

  • has not received prior treatment.

Participants in this study will receive one of the following study treatments:
  • Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic.

  • Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home.

  • Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home.

The study team will monitor how each participant responds to the study treatment for up to about 3 years.

Detailed Description

The purpose of the study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of-care chemotherapy in participants with previously untreated BRAF V600E-mutant mCRC. Since encorafenib has not previously been combined with chemotherapy, the tolerability and PK of EC in combination with mFOLFOX6 and in combination with FOLFIRI will be evaluated in separate cohorts in the safety lead-in portion of the trial in order to identify which chemotherapy combination is to be used in the Phase 3 portion of the study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
765 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
Actual Study Start Date :
Dec 21, 2020
Anticipated Primary Completion Date :
Sep 16, 2024
Anticipated Study Completion Date :
Nov 15, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Safety Lead-in Cohort 1

Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks

Drug: Encorafenib
75 mg capsules
Other Names:
  • Braftovi, PF-07263896, LGX818, ONO-7702
  • Drug: Cetuximab
    Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
    Other Names:
  • Erbitux
  • Drug: Irinotecan
    Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
    Other Names:
  • Campostar
  • Drug: Leucovorin
    Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
    Other Names:
  • Wellcovorin, Fusilev, Khapzory
  • Drug: 5-FU
    Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
    Other Names:
  • Fluorouracil
  • Experimental: Safety Lead-in Cohort 2

    Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks

    Drug: Encorafenib
    75 mg capsules
    Other Names:
  • Braftovi, PF-07263896, LGX818, ONO-7702
  • Drug: Cetuximab
    Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
    Other Names:
  • Erbitux
  • Drug: Oxaliplatin
    Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
    Other Names:
  • Eloxatin
  • Drug: Leucovorin
    Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
    Other Names:
  • Wellcovorin, Fusilev, Khapzory
  • Drug: 5-FU
    Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
    Other Names:
  • Fluorouracil
  • Experimental: Phase 3 Arm A

    Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks

    Drug: Encorafenib
    75 mg capsules
    Other Names:
  • Braftovi, PF-07263896, LGX818, ONO-7702
  • Drug: Cetuximab
    Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
    Other Names:
  • Erbitux
  • Experimental: Phase 3 Arm B

    Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks

    Drug: Encorafenib
    75 mg capsules
    Other Names:
  • Braftovi, PF-07263896, LGX818, ONO-7702
  • Drug: Cetuximab
    Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
    Other Names:
  • Erbitux
  • Drug: Oxaliplatin
    Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
    Other Names:
  • Eloxatin
  • Drug: Irinotecan
    Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
    Other Names:
  • Campostar
  • Drug: Leucovorin
    Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
    Other Names:
  • Wellcovorin, Fusilev, Khapzory
  • Drug: 5-FU
    Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
    Other Names:
  • Fluorouracil
  • Active Comparator: Phase 3 Arm C

    Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions)

    Drug: Oxaliplatin
    Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
    Other Names:
  • Eloxatin
  • Drug: Irinotecan
    Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
    Other Names:
  • Campostar
  • Drug: Leucovorin
    Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
    Other Names:
  • Wellcovorin, Fusilev, Khapzory
  • Drug: 5-FU
    Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
    Other Names:
  • Fluorouracil
  • Drug: Capecitabine
    150 mg or 500 mg Tablet
    Other Names:
  • Xeloda
  • Drug: Bevacizumab
    Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
    Other Names:
  • Zirabev
  • Outcome Measures

    Primary Outcome Measures

    1. Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs) [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Incidence of dose limiting toxicity defined as any adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment

    2. Phase 3: Progression free survival, by blinded independent review [Duration of Phase 3, approximately 34 months]

      Progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib and cetuximab + mFOLFOX6 (Arm B) vs the Control Arm (Arm C)

    Secondary Outcome Measures

    1. Safety Lead-in: Incidence of adverse events [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship as assessed by CTCAE 4.03

    2. Safety Lead-in: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion.

    3. Safety Lead-in: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

    4. Safety Lead-in: Overall response rate by investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI

    5. Safety Lead-in: Duration of response by Investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI

    6. Safety Lead-in:Progression free survival by Investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI

    7. Safety Lead-in: Time to response by Investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI

    8. Safety Lead-in: Overall survival [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]

      Overall survival defined as the time from the first dose to death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI

    9. Phase 3: Overall survival and Progression free survival by blinded independent review [Duration of Phase 3, approximately 34 months]

      Overall survival, defined as the time from the date of randomization to death due to any cause: encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B) and progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C)

    10. Phase 3: Overall response rate by blinded independent review and by Investigator [Duration of Phase 3, approximately 34 months]

      Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)

    11. Phase 3: Duration of response by blinded independent review and by Investigator [Duration of Phase 3, approximately 34 months]

      Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)

    12. Phase 3: Time to response by blinded independent review and by Investigator [Duration of Phase 3, approximately 34 months]

      Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)

    13. Phase 3: Progression free survival by Investigator [Duration of Phase 3, approximately 34 months]

      Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause:: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)

    14. Phase 3: Progression free survival 2 by Investigator [Duration of Phase 3, approximately 34 months]

      Progression free survival 2, defined as the time from the date of randomization to the second objective disease progression per RECIST v1.1, or death from any cause, whichever occurs first: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6

    15. Phase 3: Incidence of adverse events [Duration of Phase 3, approximately 34 months]

      An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)

    16. Phase 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms [Duration of Phase 3, approximately 34 months]

      Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)

    17. Phase 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) [Duration of Phase 3, approximately 34 months]

      EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.

    18. Phase 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire [Duration of Phase 3, approximately 34 months]

      The EQ-5D-5L is a standardized measure of health utility that provides a single index value for the participant's health status. It is frequently used for economic evaluations of health care and has been shown to be a valid and reliable instrument, and comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitively undemanding, taking about 2 minutes to complete

    19. Phase 3: Change from Baseline in the Patient Global Impression of Severity (PGIS) [Duration of Phase 3, approximately 34 months]

      The PGIS is a single-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time.

    20. Phase 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires [Duration of Phase 3, approximately 34 months]

      The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in symptoms or quality of life since starting treatment.

    21. Phase 3: Confirm the MSI-status in tumor tissue [Once, pre-treatment]

      Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue

    22. Phase 3: Determine the correlation between cfDNA genetic alterations and clinical outcome [Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 15 and Cycle 7 Day 1. Each cycle is 28 days for all treatments except for oxaliplatin/capecitabine treatment which is 21 days]

      BRAF V600E variant allele fraction (VAF) and/or overall mean VAF from cfDNA analysis of plasma samples collected at baseline and on treatment

    23. Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746, irinotecan and SN-38 [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]

    24. Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38 [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days. Each cycle is 28 days]

    25. Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38 [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]

    26. Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]

    27. Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]

    28. Safety Lead-in: Clearance of irinotecan, SN-38 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]

      Changes in exposures of irinotecan and its metabolite (SN-38) on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 1 (encorafenib and cetuximab + FOLFIRI) Changes in exposures of oxaliplatin on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 2 (encorafenib and cetuximab + mFOLFOX6)

    29. Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]

    30. Phase 3: Trough concentrations of encorafenib and its metabolite LHY746 [Predose on Cycle 1 through Cycle 6. Each cycle is 28 days]

      Trough plasma concentrations in all patients in Arm A and Arm B

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    16 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Safety Lead-In = Male/female ≥ 18 years old

    • Phase 3: Male/female ≥ 16 years old (where permitted locally)

    • Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation

    • Prior systemic treatment in metastatic setting

    • SLI: 0-1 regimens

    • Phase 3: None

    • Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment

    • Measurable disease (Phase 3)/ Measurable or evaluable disease (Safety Lead-in)

    • ECOG PS 0-1

    • Adequate organ function

    Exclusion Criteria:
    • Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition

    • Active bacterial or viral infections in 2 weeks prior to starting dosing

    • Symptomatic brain metastases

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mayo Clinic - Phoenix Oncology Pharmacy Phoenix Arizona United States 85054
    2 Mayo Clinic Hospital Phoenix Arizona United States 85054
    3 Mayo Clinic in Arizona - Scottsdale Scottsdale Arizona United States 85259
    4 Tower Hematology Oncology Medical Group (THO) Beverly Hills California United States 90211
    5 Keck Hospital of USC Los Angeles California United States 90033
    6 LAC & USC Medical Center Los Angeles California United States 90033
    7 USC / Norris Comprehensive Cancer Center Los Angeles California United States 90033
    8 USC/Norris Comprehensive Cancer Center / Investigational Drug Services Los Angeles California United States 90033
    9 USC/Norris Comprehensive Cancer Center Los Angeles California United States 90033
    10 Cedars- Sinai Medical Center Los Angeles California United States 90048
    11 Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute Los Angeles California United States 90048
    12 Cedars-Sinai Medical Center Los Angeles California United States 90048
    13 Keck Hospital of USC Pasadena Pasadena California United States 91105
    14 Torrance Memorial Medical Center (TMMC) Torrance California United States 90505
    15 Georgetown University Medical Center Washington District of Columbia United States 20007
    16 Medstar Georgetown University Hospital Washington District of Columbia United States 20007
    17 Mount Sinai Comprehensive Cancer Center, Aventura Aventura Florida United States 33180
    18 Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center Coral Gables Florida United States 33146
    19 Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center Fort Lauderdale Florida United States 33308
    20 Mayo Clinic Florida Jacksonville Florida United States 32224
    21 Mount Sinai Comprehensive Cancer Center Miami Beach Florida United States 33140
    22 Mount Sinai Medical Center Miami Beach Florida United States 33140
    23 Sylvester Comprehensive Cancer Center Miami Florida United States 33136
    24 Baptist Hospital of Miami Miami Florida United States 33176
    25 Miami Cancer Institute Miami Florida United States 33176
    26 Orlando Health Cancer Institute Orlando Florida United States 32806
    27 Orlando Health, Inc. Orlando Florida United States 32806
    28 Orlando Health, Inc Orlando Florida United States 32806
    29 BRCR Medical Center Inc. Plantation Florida United States 33322
    30 Lewis Cancer & Research Pavilion at St Joseph's/Candler Health System Savannah Georgia United States 31405
    31 Lewis Cancer & Research Pavilion Pharmacy Savannah Georgia United States 31405
    32 St. Joseph's/Candler Health System, Inc. Savannah Georgia United States 31405
    33 Summit Cancer Care, P.C. Savannah Georgia United States 31405
    34 Summit Cancer Care Savannah Georgia United States 31405
    35 St. Joseph's/Candler Health System, Inc. Savannah Georgia United States 31419
    36 UChicago Medicine - River East Chicago Illinois United States 60611
    37 The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy Chicago Illinois United States 60637
    38 University of Chicago Medical Center Chicago Illinois United States 60637
    39 UChicago Medicine at Ingalls - Flossmoor Flossmoor Illinois United States 60422
    40 UChicago Medicine Ingalls Memorial Harvey Illinois United States 60426
    41 University of Chicago Comprehensive Cancer Center at Silver Cross Hospital New Lenox Illinois United States 60451
    42 The University of Chicago Medicine Center for Advanced Care Orland Park Orland Park Illinois United States 60462
    43 UChicago Medicine at Ingalls - Tinley Park Tinley Park Illinois United States 60477
    44 Ochsner Clinic Foundation Research Pharmacy New Orleans Louisiana United States 70121
    45 Ochsner Clinic Foundation New Orleans Louisiana United States 70121
    46 University of Michigan Hospitals Ann Arbor Michigan United States 48109
    47 University of Michigan Ann Arbor Michigan United States 48109
    48 Mayo Clinic Rochester Rochester Minnesota United States 55905
    49 Mayo Clinic Rochester Minnesota United States 55905
    50 Siteman Cancer Center - West County Creve Coeur Missouri United States 63141
    51 Siteman Cancer Center - North County Florissant Missouri United States 63031
    52 Barnes- Jewish Hospital Saint Louis Missouri United States 63110
    53 Washington University School of Medicine Saint Louis Missouri United States 63110
    54 Siteman Cancer Center - South County Saint Louis Missouri United States 63129
    55 Siteman Cancer Center - St Peters Saint Peters Missouri United States 63376
    56 St Vincent Healthcare Billings Montana United States 59101
    57 St. Vincent Frontier Cancer Center Billings Montana United States 59102
    58 Oncology Hematology West PC dba Nebraska Cancer Specialists Omaha Nebraska United States 68114
    59 Oncology Hematology West PC dba Nebraska Cancer Specialists Omaha Nebraska United States 68124
    60 Oncology Hematology West PC dba Nebraska Cancer Specialists Omaha Nebraska United States 68130
    61 Oncology Hematology West, PC dba Nebraska Cancer Specialists - IP Storage Omaha Nebraska United States 68130
    62 Oncology Hematology West PC dba Nebraska Cancer Specialists Papillion Nebraska United States 68046
    63 Memorial Sloan Kettering Cancer Center - Basking Ridge Basking Ridge New Jersey United States 07920
    64 Summit Medical Group Berkeley Heights New Jersey United States 07922
    65 Summit Medical Group Florham Park New Jersey United States 07932
    66 Memorial Sloan Kettering Cancer Center- Monmouth Middletown New Jersey United States 07748
    67 Memorial Sloan Kettering Cancer Center- Bergen Montvale New Jersey United States 07645
    68 North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists Babylon New York United States 11702
    69 North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists Bronx New York United States 10469
    70 Memorial Sloan Kettering Cancer Center Commack Commack New York United States 11725
    71 Memorial Sloan Kettering Cancer Center - Westchester Harrison New York United States 10604
    72 Memorial Sloan Kettering Cancer Center New York New York United States 10022
    73 North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists New York New York United States 10028
    74 Memorial Sloan Kettering Cancer Center - Main Campus New York New York United States 10065
    75 North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists Patchogue New York United States 11772
    76 North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists Port Jefferson Station New York United States 11776
    77 North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists Riverhead New York United States 11901
    78 Memorial Sloan Kettering Cancer Center- Nassau Uniondale New York United States 11553
    79 Carolinas Medical Center Charlotte North Carolina United States 28203
    80 Carolinas Medical Center Investigational Drug Services Charlotte North Carolina United States 28204
    81 Levine Cancer Institute Charlotte North Carolina United States 28204
    82 Atrium Health Mercy Charlotte North Carolina United States 28207
    83 Atrium Health Pineville Charlotte North Carolina United States 28210
    84 Levine Cancer Institute - Southpark Charlotte North Carolina United States 28211
    85 Atrium Health University City Charlotte North Carolina United States 28262
    86 Levine Cancer Institute University City Charlotte North Carolina United States 28262
    87 Atrium Health Cabarrus Concord North Carolina United States 28025
    88 Levine Cancer Institute - Concord Concord North Carolina United States 28025
    89 Atrium Health Union Monroe North Carolina United States 28112
    90 Investigational Drug Service, The Ohio State University Wexner Medical Center Columbus Ohio United States 43210
    91 The Ohio State University James Cancer Hospital and Solove Research Institute Columbus Ohio United States 43210
    92 Stefanie Spielman Comprehensive Breast Cancer Columbus Ohio United States 43212
    93 Martha Morehouse Medical Plaza Columbus Ohio United States 43221
    94 University of Oklahoma Health Sciences Center, OU Health Stephenson Cancer Center Oklahoma City Oklahoma United States 73104
    95 Providence Cancer Institute Franz Clinic Portland Oregon United States 97213
    96 Providence Portland Medical Center Portland Oregon United States 97213
    97 Providence Onc and Heme Care Clinic - Westside Portland Oregon United States 97225
    98 Providence Oncology and Hematology Care Clinic - Westside Portland Oregon United States 97225
    99 Providence St Vincent Medical Center Portland Oregon United States 97225
    100 Providence St. Vincent Medical Center Portland Oregon United States 97225
    101 AHN Cancer Institute at Jefferson Hospital Jefferson Hills Pennsylvania United States 15025
    102 AHN Cancer Institute Forbes Hospital Monroeville Pennsylvania United States 15146
    103 AHN Cancer Institute - Allegheny General Hospital Pittsburgh Pennsylvania United States 15212
    104 AHN Cancer Institute Pharmacy Pittsburgh Pennsylvania United States 15212
    105 AHN Cancer Institute West Penn Hospital Pittsburgh Pennsylvania United States 15224
    106 UPMC Hillman Cancer Center Investigational Drug Service Pittsburgh Pennsylvania United States 15232
    107 UPMC Hillman Cancer Center Pittsburgh Pennsylvania United States 15232
    108 Wexford Health and Wellness Pavilion Wexford Pennsylvania United States 15090
    109 Vanderbilt Health Clinic at Walgreens Clarksville Clarksville Tennessee United States 37043
    110 Vanderbilt Health Clinic at Walgreens Cool Springs Franklin Tennessee United States 37067
    111 Vanderbilt Health Clinic at Walgreens Gallatin Gallatin Tennessee United States 37066
    112 The West Clinic. PLLC. dba West Cancer Center Germantown Tennessee United States 38138
    113 Vanderbilt Health Clinic at Walgreens Hendersonville Hendersonville Tennessee United States 37075
    114 Vanderbilt Health Clinic at Walgreens Hermitage Hermitage Tennessee United States 37076
    115 Vanderbilt Health Clinic at Walgreens La Vergne La Vergne Tennessee United States 37086
    116 Vanderbilt Health Clinic at Walgreens Lebanon Lebanon Tennessee United States 37087
    117 The West Clinic PLLC dba West Cancer Center Memphis Tennessee United States 38104
    118 Vanderbilt Health Clinic at Walgreens Murfreesboro Murfreesboro Tennessee United States 37128
    119 Vanderbilt Health Clinic at Walgreens Belle Meade Nashville Tennessee United States 37205
    120 Vanderbilt Health Clinic at Walgreens Nippers Corner Nashville Tennessee United States 37211
    121 Vanderbilt Health Clinic at Walgreens Donelson Nashville Tennessee United States 37214
    122 Vanderbilt Health Clinic at Walgreens Hart Lane Nashville Tennessee United States 37216
    123 Vanderbilt Health Clinic at Walgreens Bellevue Nashville Tennessee United States 37221
    124 Vanderbilt-Ingram Cancer Center Nashville Tennessee United States 37232-6307
    125 Henry-Joyce Cancer Center Nashville Tennessee United States 37232
    126 Vanderbilt Oncology IDS Pharmacy Nashville Tennessee United States 37232
    127 Vanderbilt Health Clinic at Walgreens Smyrna Smyrna Tennessee United States 37167
    128 The University of Texas MD Anderson Cancer Center Houston Texas United States 77030-4009
    129 The University of Texas MD Anderson Cancer Center Houston Texas United States 77030
    130 VCU Health System, Investigational Drug Service Pharmacy Richmond Virginia United States 23298
    131 Virginia Commonwealth University Massey Cancer Center Richmond Virginia United States 23298
    132 Seattle Cancer Care Alliance Seattle Washington United States 98109
    133 University of Washington Medical Center Seattle Washington United States 98195
    134 University of Wisconsin Clinical Science Center Madison Wisconsin United States 53792
    135 Froedtert Hospital and the Medical College of Wisconsin Milwaukee Wisconsin United States 53226
    136 Centro Medico San Roque San Miguel De Tucumán Tucumán Argentina 4000
    137 Centro Medico San Roque Tucuman Tucumán Argentina 4000
    138 Instituto Médico Especializado Alexander Fleming Ciudad Autónoma de Buenos Aires Argentina 1426
    139 Clinica Universitaria Reina Fabiola Cordoba Argentina X5004FHP
    140 Hospital Privado Centro Médico de Córdoba Cordoba Argentina X5016KEH
    141 Hospital Privado Centro Médico de Córdoba Córdoba Argentina X5016KEH
    142 Liverpool Hospital Liverpool New South Wales Australia 2170
    143 Slade Pharmacy Mount Kuring-Gai New South Wales Australia 2080
    144 Chris O'Brien Lifehouse Newtown New South Wales Australia 2042
    145 GenesisCare - North Shore St Leonards New South Wales Australia 2065
    146 Northern Cancer Institute St Leonards New South Wales Australia 2065
    147 Royal Brisbane & Women's Hospital Herston Queensland Australia 4029
    148 Princess Alexandra Hospital Woolloongabba Queensland Australia 4102
    149 The Queen Elizabeth Hospital Adelaide South Australia Australia 5011
    150 Monash Health Clayton Victoria Australia 3168
    151 Austin Health Heidelberg Victoria Australia 3084
    152 Peter MacCallum Cancer Centre Melbourne Victoria Australia 3000
    153 Alfred Health Melbourne Victoria Australia 3004
    154 The Alfred Hospital Melbourne Victoria Australia 3004
    155 Université Libre de Bruxelles - Hôpital Erasme Brussels Bruxelles-capitale, Région DE Belgium 1070
    156 Cliniques universitaires Saint-Luc Brussels Bruxelles-capitale, Région DE Belgium 1200
    157 Grand Hôpital de Charleroi Charleroi Hainaut Belgium 6000
    158 CHR Verviers East Belgium Verviers Liège Belgium 4800
    159 AZ Groeninge Campus Kennedylaan Kortrijk West-vlaanderen Belgium 8500
    160 ZNA Middelheim Antwerpen Belgium 2020
    161 UZ Leuven Leuven Belgium 3000
    162 Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman Liège Belgium 4000
    163 Hospital Bruno Born Lajeado RIO Grande DO SUL Brazil 95900-000
    164 Hospital Bruno Born Lajeado RIO Grande DO SUL Brazil 95900-010
    165 Hospital de Clinicas de Porto Alegre Porto Alegre RIO Grande DO SUL Brazil 90035-903
    166 INCA Rio de Janeiro RJ Brazil 20230-130
    167 Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA Rio de Janeiro RJ Brazil 20230-130
    168 Clinica de Oncologia Reichow Blumenau Santa Catarina Brazil 89010-340
    169 Clínica de Neoplasias Litoral Itajaí Santa Catarina Brazil 88301-220
    170 CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC Santo Andre SP Brazil 09060-650
    171 Fundacao do ABC-Faculdade de Medicina do ABC Santo Andre SP Brazil 09060-870
    172 CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC Santo André SP Brazil 09060-650
    173 Fundação Pio XII - Hospital de Câncer de Barretos Barretos SÃO Paulo Brazil 14784400
    174 Medical School Famerp-HB-FUNFARME_Do not use - Duplicate facility Sao jose do Rio Preto SÃO Paulo Brazil 15090-000
    175 Fundação Faculdade Regional de Medicina de São José do Rio Preto São José do Rio Preto SÃO Paulo Brazil 15090000
    176 MHAT Uni Hospital OOD Panagyurishte Pazardzhik Bulgaria 4500
    177 MHAT "Dr. Tota Venkova" AD Gabrovo Bulgaria 5300
    178 Complex Oncology Center - Plovdiv EOOD Plovdiv Bulgaria 4000
    179 MHAT Central Onco Hospital OOD Plovdiv Bulgaria 4000
    180 Medical Center Nadezhda Clinical EOOD Sofia Bulgaria 1303
    181 Acibadem City Clinic MHAT Tokuda Sofia Bulgaria 1407
    182 University Multiprofile Hospital for Active Treatment Sofiamed Sofia Bulgaria 1750
    183 Tom Baker Cancer Centre Calgary Alberta Canada T2N 4N2
    184 Cross Cancer Institute Edmonton Alberta Canada T6G 1Z2
    185 Kingston Health Sciences Centre-Kingston General Hospital Site Kingston Ontario Canada K7L 2V7
    186 London Regional Cancer Program, London Health Sciences Centre London Ontario Canada N6A 5W9
    187 Sunnybrook Health Sciences Centre Toronto Ontario Canada M4N 3M5
    188 Centre Intégré de Santé et de Services Sociaux (CISSS) de Laval / Hôpital de la Cité-de-la-Sant Laval Quebec Canada H7M 3L9
    189 Jewish General Hospital Montreal Quebec Canada H3T 1E2
    190 Anhui Provincial Cancer Hospital Hefei Anhui China 230031
    191 Cancer Hospital Chinese Academy of Medical Science Beijing Beijing China 100021
    192 Beijing Cancer hospital Beijing Beijing China 100142
    193 Beijing Hospital Beijing Beijing China 100730
    194 Fujian Medical University Union Hospital-1 Bingfanglou Fuzhou Fujian China 350001
    195 Affiliated Tumor Hospital of Guangxi Medical University Nanning Guangxi China 530021
    196 Henan provincial people's hospital Zhengzhou Henan China 450003
    197 The Second Xiangya Hospital of Central South University Changsha Hunan China 410011
    198 The Third Xiangya Hospital of Central South University Changsha Hunan China 410013
    199 Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School Nanjing Jiangsu China 210008
    200 Shengjing Hospital Of China Medical University Shenyang Liaoning China 110022
    201 Jinan Central Hospital Jinan Shandong China 250013
    202 The Affiliated Hospital of Qingdao University Qingdao Shandong China 266031
    203 Shanghai Jiaotong University School of Medicine Ruijin Hospital Shanghai Shanghai China 200025
    204 Shanghai General Hospital Shanghai Shanghai China 200080
    205 Sichuan Province Cancer Hospital Chengdu Sichuan China 610041
    206 Yunnan Cancer Hospital(The Third Affiliated Hospital of Kunming Medical University) Kunming Yunnan China 650118
    207 The second Affiliated Hospital of College of Medicine, Zhejiang University Hangzhou Zhejiang China 310000
    208 Peking University First Hospital Beijing China 100034
    209 Fudan University Shanghai Cancer Center Shanghai China 201321
    210 Fakultní nemocnice Brno Bohunice Brno Brno-město Czechia 625 00
    211 Fakultni nemocnice Hradec Kralove Hradec Kralove Hradec Králové Czechia 500 05
    212 Fakultni Thomayerova nemocnice Prague Praha 4 Czechia 14059
    213 Fakultni nemocnice Olomouc Olomouc Czechia 779 00
    214 Fakultni nemocnice v Motole Praha 5 Czechia 150 06
    215 Fakultni nemocnice Bulovka Praha 8 Czechia 180 81
    216 Aalborg Universitetshospital, Syd Aalborg Nordjylland Denmark 9000
    217 Vejle Hospital-Sygehus Lillebaelt Vejle Syddanmark Denmark 7100
    218 Vejle Sygehus Vejle Syddanmark Denmark 7100
    219 Aalborg Universitetshospital Aalborg Denmark 9000
    220 Rigshospitalet Copenhagen Denmark 2100
    221 Herlev Hospital Herlev Denmark 2730
    222 Odense University Hospital Odense C Denmark 5000
    223 Docrates Syöpäsairaala Helsinki Nyland Finland 00180
    224 Tampereen yliopistollinen sairaala Tampere Pirkanmaa Finland 33520
    225 Helsinki University Central Hospital Helsinki Finland 00029
    226 Oulu University Hospital Oulu Finland 90220
    227 Satakunnan Keskussairaala Pori Finland 28500
    228 Turku University Hospital Turku Finland 20520
    229 Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie Muenchen Bayern Germany 81737
    230 Institut für Klinisch Onkologische Forschung Frankfurt Hessen Germany 60488
    231 Medizinische Hochschule Hannover Hannover Lower Saxony Germany 30625
    232 Medizinische Hochschule Hannover Hannover Niedersachsen Germany 30625
    233 Universitätsklinikum Leipzig Leipzig Sachsen Germany 04103
    234 Radiologie Berlin Berlin - Charlottenburg Germany 10719
    235 Onkologische Schwerpunktpraxis Kurfuerstendamm Berlin Germany 10707
    236 Waage Apotheke Berlin Germany 10709
    237 HELIOS Klinikum Berlin Buch GmbH Berlin Germany 13125
    238 Helios Klinikum Berlin-Buch Berlin Germany 13125
    239 Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus Dresden Germany 01307
    240 Universitätsklinikum Carl Gustav Carus Dresden Dresden Germany 01307
    241 Facharztzentrum Eppendorf Hamburg Germany 20249
    242 ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld Hamburg Germany 22045
    243 Radiologie im Israelitischen Krankenhaus Hamburg Germany 22297
    244 Klinikum Oldenburg AöR Oldenburg Germany 26133
    245 Klinikum Oldenburg AöR Oldenburg Germany 26135
    246 Rajiv Gandhi Cancer Institute And Research Centre New Delhi Delhi India 110 085
    247 Rajiv Gandhi Cancer Institute And Research Centre New Delhi Delhi India 110085
    248 Tata Memorial Hospital Mumbai Maharashtra India 400012
    249 Deenanath Mangeshkar Hospital & Research Centre Pune Maharashtra India 411 004
    250 Sahyadri Speciality Hospital Pune Maharashtra India 411 004
    251 Bhakti Vedanta Hospital and Research Institute Thane Maharashtra India 401107
    252 R K Birla Cancer Center, SMS Hospital Jaipur Rajasthan India 302004
    253 Sawai Man Singh Medical College Hospital (SMS Hospital) Jaipur Rajasthan India 302004
    254 Azienda Ospedaliera Universitaria di Cagliari - Presidio Policlinico Universitario "D.Casula" Monserrato (CA) Cagliari Italy 09042
    255 IRCCS Casa Sollievo della Sofferenza San Giovanni Rotondo Foggia Italy 71013
    256 ASST Grande Ospedale Metropolitano Niguarda Milan Milano Italy 20162
    257 Fondazione del Piemonte per l'Oncologia - Istituto di Candiolo IRCCS Candiolo Torino Italy 10060
    258 Azienda Ospedaliero Universitaria San Luigi Gonzaga Orbassano Torino Italy 10043
    259 Fondazione Poliambulanza Istituto Ospedaliero Brescia Italy 25124
    260 Istituto Europeo di Oncologia IRCCS Milano Italy 20141
    261 Azienda Ospedaliera Universitaria dell'Università "Luigi Vanvitelli" di Napoli Napoli Italy 80131
    262 IRCCS Istituto Oncologico Veneto (IOV) Padova Italy 35128
    263 Azienda USL - IRCCS di Reggio Emilia - Arcispedale Santa Maria Nuova Reggio Emilia Italy 42123
    264 Chiba cancer center Chiba-shi Chiba Japan 260-8717
    265 National Cancer Center Hospital East Kashiwa Chiba Japan 277-8577
    266 National Hospital Organization Shikoku Cancer Center Matsuyama Ehime Japan 791-0280
    267 Hokkaido University Hospital Sapporo Hokkaido Japan 060-8648
    268 Kanazawa University Hospital Kanazawa Ishikawa Japan 920-8641
    269 St. Marianna University Hospital Kawasaki Kanagawa Japan 216-8511
    270 Kanagawa cancer center Yokohama Kanagawa Japan 2418515
    271 Aichi Cancer Center Hospital Nagoya Nagoya, Aichi Japan 464-8681
    272 Osaka Prefectural Hospital Organization Osaka International Cancer Institute Osaka-shi Osaka Japan 5418567
    273 Kindai University Hospital Osakasayama Osaka Japan 589-8511
    274 Osaka University Hospital Suita Osaka Japan 565-0871
    275 Osaka Medical and Pharmaceutical University Hospital Takatsuki Osaka Japan 569-8686
    276 Saitama Medical University International Medical Center Hidaka-city Saitama Japan 350-1298
    277 Saitama Prefectural Cancer Center Ina-machi Saitama Japan 362-0806
    278 Shizuoka Cancer Center Nagaizumi Shizuoka Japan 411-8777
    279 National Cancer Center Hospital Chuo-ku Tokyo Japan 104-0045
    280 Japanese Foundation for Cancer Research Koto-ku Tokyo Japan 135-8550
    281 National Hospital Organization Kyushu Cancer Center Fukuoka Japan 811-1395
    282 National Hospital Organization - Osaka National Hospital - Institute For Clinical Research Osaka Japan 540-0006
    283 Keio University Hospital Tokyo Japan 1600035
    284 National Cancer Center Goyang-si Gyeonggi-do Korea, Republic of 10408
    285 Kyungpook National University Hospital Daegu Taegu-kwangyǒkshi Korea, Republic of 41404
    286 Dong-A University Hospital Busan Korea, Republic of 49201
    287 Kyungpook National University Chilgok Hospital Daegu Korea, Republic of 41404
    288 Gachon University Gil Medical Center Incheon Korea, Republic of 21565
    289 Chonnam National University Hwasun Hospital Pharmacy Jeonnam Korea, Republic of 58128
    290 Chonnam National University Hwasun Hospital Jeonnam Korea, Republic of 58128
    291 Korea University Anam Hospital Seoul Korea, Republic of 02841
    292 Seoul National University Hospital Seoul Korea, Republic of 03080
    293 Severance Hospital, Yonsei University Health System Seoul Korea, Republic of 03722
    294 Asan Medical Center Seoul Korea, Republic of 05505
    295 Samsung Medical Center Seoul Korea, Republic of 06351
    296 Accelerium, S. de R.L. de C.V. Monterrey Nuevo LEON Mexico 64000
    297 Centro de Investigacion Clinica de Oaxaca Oaxaca Mexico 68020
    298 Maastricht UMC+ Maastricht Limburg Netherlands 6229 HX
    299 Catharina Ziekenhuis Eindhoven Noord-brabant Netherlands 5623 EJ
    300 Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) Amsterdam Noord-holland Netherlands 1066 CX
    301 Haaglanden Medisch Centrum Den Haag Zuid-holland Netherlands 2512 VA
    302 Haaglanden MC - locatie Westeinde Den Haag Netherlands
    303 Haaglanden MC - locatie Westeinde Leidschendam Netherlands 2262 BA
    304 Maastricht University Medical Center Maastricht Netherlands 6229 HX
    305 Universitair Medisch Centrum Utrecht Utrecht Netherlands 3584 CX
    306 Tauranga Hospital Tauranga BAY OF Plenty New Zealand 3112
    307 Auckland City Hospital Auckland New Zealand 1023
    308 Haukeland University Hospital Bergen Hordaland Norway 5021
    309 Stavanger Universitetssykehus Stavanger Rogaland Norway 4011
    310 St. Olavs hospital Trondheim Sør-trøndelag Norway 7030
    311 Sørlandet Sykehus Kristiansand Kristiansand Vest-agder Norway N-4615
    312 Oslo universitetssykehus, Radiumhospitalet Oslo Norway 0379
    313 Oslo Universitetssykehus Ullevål Oslo Norway 0450
    314 Przychodnia Lekarska KOMED Konin Wielkopolskie Poland 62-500
    315 Szpital Specjalistyczny Podkarpacki Ósrodek Onkologiczny w Brzozowie Brzozow Poland 36-200
    316 Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii Bytom Poland 41-902
    317 Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii Bytom Poland 41902
    318 COPERNICUS PL sp. z. o. o. Wojewodzkie Centrum Onkologii w Gdansku Ambulatoryjna Gdansk Poland 80-219
    319 COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii Gdansk Poland 80-219
    320 Przychodnia Lekarska KOMED Konin Poland 62-500
    321 Regional Specialised Hospital No. 4 in Bytom Bytom Śląskie Poland 41-902
    322 Sbi "City Clinical Hospital №1 Nalchik Kabardino-balkarian Republic Russian Federation 360003
    323 State budget institution of healthcare of Mordovia Republic "Republic Oncology Dispensary" Saransk Republic OF Mordovia Russian Federation 430032
    324 Private Medical Institution "Euromedservice" Pushkin Saint-petersburg Russian Federation 196603
    325 Private Medical Institution "Euromedservice" Pushkin Sankt-peterburg Russian Federation 196603
    326 GBUZ Chelyabinsk Russian Federation 454087
    327 Kaluga Regional Clinical Oncology Center Kaluga Russian Federation 248007
    328 FSAEI HE I.M Sechenov First MSMU MoH Russia (Sechenovskiy University), Moscow Russian Federation 119991
    329 BHI of Omsk Region "Clinical Oncology Dispensary" Omsk Russian Federation 644013
    330 BHI of Omsk Region "Clinical Oncology Dispensary" Omsk Russian Federation 644046
    331 State Budgetary Healthcare Institution "Orenburg Regional Clinical Oncological Dispensary" Orenburg Russian Federation 460021
    332 LLC "EuroCityClinic" Saint Petersburg Russian Federation 197022
    333 LLC "Medicina Severnoy Stolitsy" Saint-Petersburg Russian Federation 191025
    334 LLC "Severo-Zapadny Medical Center" Saint-Petersburg Russian Federation 192007
    335 Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of St. Petersburg Saint-Petersburg Russian Federation 195271
    336 FSBI "Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov St. Petersburg Russian Federation 197758
    337 SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan Ufa Russian Federation 450054
    338 SHI YR Regional Clinical Oncology Hospital Yaroslavl Russian Federation 150040
    339 SHI YR Regional Clinical Oncology Hospital Yaroslavl Russian Federation 150054
    340 SHI YR Regional Clinical Oncology Hospital Yaroslav Russian Federation 150054
    341 Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica Banska Bystrica Slovakia 974 01
    342 Onkologicky ustav sv. Alzbety s.r.o. Bratislava Slovakia 812 50
    343 Narodny Onkologicky Ustav Bratislava Slovakia 833 10
    344 Vychodoslovensky onkologicky ustav, a.s. Kosice Slovakia 04191
    345 POKO Poprad s.r.o. Poprad Slovakia 058 01
    346 Cancercare Rondebosch Oncology Rondebosch Cape Town South Africa 7700
    347 Cancercare Langenhoven Drive Oncology Centre Port Elizabeth Eastern CAPE South Africa 6045
    348 Cancercare Langenhoven Drive Oncology Centre Port Elizabeth Eastern CAPE South Africa 6055
    349 Life Groenkloof Pretoria Gauteng South Africa 0181
    350 Cape Town Oncology Trials Cape Town Western CAPE South Africa 7570
    351 GVI Oncology Cape Town Western CAPE South Africa 7570
    352 Mary Potter Oncology Centre Pretoria South Africa 0181
    353 Complejo Hospitalario Universitario Santiago de Compostela Santiago de Compostela A Coruña Spain 15706
    354 Hospital General Universitario de Elche Elche Alicante Spain 03203
    355 ICO L'Hospitalet (Hospital Duran i Reynals) Hospitalet de Llobregat Barcelona Spain 08908
    356 Hospital Universitario Vall d'Hebron Barcelona Spain 08035
    357 Hospital Clinic Barcelona Barcelona Spain 08036
    358 Hospital General Universitario Gregorio Marañon Madrid Spain 28007
    359 Hospital Universitario Ramon Y Cajal Madrid Spain 28034
    360 Hospital Universitario 12 de octubre Madrid Spain 28041
    361 Hospital Universitario Virgen Del Rocio Sevilla Spain 41013
    362 Hospital Clinico Universitario de Valencia Valencia Spain 46010
    363 Hospital General Universitario de Valencia Valencia Spain 46014
    364 Hospital Universitario Miguel Servet Zaragoza Spain 50009
    365 Karolinska Universitetssjukhuset Solna Solna Stockholms LÄN [se-01] Sweden 171 64
    366 Akademiska sjukhuset Uppsala Uppsala LÄN [se-03] Sweden 751 85
    367 Norrlands universitetssjukhus Umeå Västerbottens LÄN [se-24] Sweden 90185
    368 Sahlgrenska Universitetssjukhuset Göteborg Västra Götalands LÄN [se14] Sweden 413 45
    369 Västmanlands Sjukhus Västerås Västerås Sweden 721 89
    370 Kaohsiung Medical University Chung-Ho Memorial Hospital Kaohsiung Taiwan 807
    371 China Medical University Hospital Taichung Taiwan 40447
    372 National Cheng-Kung University Hospital Tainan Taiwan 704
    373 Chi Mei Hospital, Liouying Tainan Taiwan 73657
    374 National Taiwan University Hospital Taipei Taiwan 10002
    375 Taipei Medical University Hospital Taipei Taiwan 11031
    376 Taipei Veterans General Hospital Taipei Taiwan 11217
    377 Chang Gung Medical Foundation-Linkou Branch Taoyuan Taiwan 333
    378 Medical and diagnostic center of MediX-Ray International Group LLC Israeli Oncology Hospital "LISOD" Pliuty Village KYIV Region, Obuhovskiy District Ukraine 08720
    379 Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council Dnipro Ukraine 49102
    380 PRECARPATHIAN NUCLEAR MEDICINE CENTER, Limited Liability Company Ivano-Frankivsk Ukraine 76011
    381 Ivano-Frankivsk National Medical University Ivano-Frankivsk Ukraine 76018
    382 MNPE "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Regional Council" Ivano-Frankivsk Ukraine 76018
    383 Municipal non-profit enterprise "City clinical hospital #2 named after O.O.Shalimov" Kharkiv Ukraine 61037
    384 Communal Non-Profit Enterprise "Regional Center of Oncology" Kharkiv Ukraine 61070
    385 Communal enterprise "Kryvyi Rih Oncology Dispensary" of Dnipropetrovsk Regional Council Kryvyi Rih Ukraine 50048
    386 SI "Insitute of Neurosurgery n.a.acad. A.P. Kyiv Ukraine 04050
    387 SI "Insitute of Neurosurgery n.a.acad. A.P. Kyiv Ukraine 04050
    388 Municipal non-profit enterprise of Kyiv regional council "Kyiv regional clinical hospital" Kyiv Ukraine 04107
    389 Municipal non-profit enterprise "Zaporizhzhia Regional Antitumor Center" Zaporizhzhia Regional Zaporizhzhia Ukraine 69040
    390 Freeman Hospital Newcastle upon Tyne HIGH Heaton United Kingdom NE7 7DN
    391 Royal Marsden NHS Foundation Trust Sutton Surrey United Kingdom SM2 5PT
    392 Heartlands Hospital Birmingham United Kingdom B9 5SS
    393 Royal Marsden NHS Foundation Trust London United Kingdom SW3 6JJ
    394 Hammersmith Hospital, Imperial College Healthcare NHS Trust London United Kingdom W12 0HS
    395 Charing Cross Hospital, Imperial College Healthcare NHS Trust London United Kingdom W6 8RF
    396 Churchill Hospital - Oncology Oxford United Kingdom OX3 7LE

    Sponsors and Collaborators

    • Pfizer
    • Ono Pharmaceutical Co. Ltd
    • Merck KGaA, Darmstadt, Germany

    Investigators

    • Study Director: Pfizer CT.gov Call Center, Pfizer

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Pfizer
    ClinicalTrials.gov Identifier:
    NCT04607421
    Other Study ID Numbers:
    • C4221015
    • 2020-001288-99
    • BREAKWATER
    First Posted:
    Oct 29, 2020
    Last Update Posted:
    Aug 5, 2022
    Last Verified:
    Aug 1, 2022

    Study Results

    No Results Posted as of Aug 5, 2022